Description
Utilize our advanced Long COVID Vascular Health 18-Plex Panel to explore dysfunctions in vascular and endothelial integrity, coagulation, and inflammation. This panel is designed to assess circulating factors that may indicate abnormalities in angiogenesis, coagulation, vascular function, and inflammatory responses—key aspects thought to be involved in the pathogenesis of Long COVID.
Applications in Diagnostics
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with long COVID:
- Vascular Dysfunction: Evaluate endothelial function and vascular integrity in patients with long COVID. Analytes like Endothelin-1, sICAM-1, sVCAM-1, and sP-Selectin are key indicators of endothelial activation and dysfunction.
- Coagulation Abnormalities: Assess coagulation status and thrombotic risk in long COVID patients. D-Dimer, sP-Selectin, and ADAMTS13 levels can help identify ongoing coagulation and fibrinolytic activity.
- Angiogenesis and Tissue Repair: Monitor angiogenic factors that contribute to tissue repair and regeneration in the context of long COVID. Analytes such as VEGF-C, VEGF-D, Angiopoietin-2, and PLGF are involved in angiogenesis and vascular remodeling.
- Cardiovascular Health: Investigate cardiovascular health and potential long-term effects on the heart and blood vessels. Biomarkers like HGF, Endoglin, and BMP-9 can provide insights into cardiovascular remodeling and myocardial repair.
- Inflammatory Response: Evaluate chronic inflammation and its impact on vascular health. Biomarkers such as SAA and Leptin can indicate ongoing inflammatory processes contributing to vascular pathology.
- Fibrosis and Tissue Damage: Assess fibrosis and tissue damage related to long COVID. Biomarkers like Follistatin and HB-EGF are involved in tissue remodeling and fibrotic processes.
- Metabolic Impact: Investigate the metabolic impact of long COVID on vascular health. Leptin and FGF-1 levels can provide insights into metabolic dysregulation and its effect on cardiovascular health.
A number of biomarkers detected in the Long COVID Vascular Health 18-Plex Panel are specifically associated with coagulation, which makes serum an unacceptable sample type for this assay. The Long COVID Vascular Health 18-Plex Panel is recommended for plasma only, EDTA preferred.
Leverage this panel to gain in-depth understanding and drive impactful diagnostics and targeted therapeutics in Long COVID.
Key Features:
- Comprehensive Biomarker Coverage: Provides a detailed analysis of 18 key biomarkers, ensuring a thorough diagnostic approach.
- CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
- Versatility: Use this panel to investigate dysfunctions in vascular and endothelial integrity, coagulation, and inflammation. The panel consists of circulating factors that may suggest abnormalities in angiogenesis (a response to persistent vascular injury), coagulation, vascular function and inflammatory responses, which are thought to be key features of Long COVID pathogenesis.
- Reference intervals: Are available for PLASMA-EDTA.
- Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical applications.
- Swift and Reliable Turnaround Time: We pride ourselves on a rapid turnaround time, with results typically delivered within 5 business days of receiving your specimen and payment.
Discover the power of precision with our Long COVID Vascular Health 18-Plex Panel, expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency.
Certified Excellence in Diagnostic Testing
Eve Technologies is certified by the Centers for Medicare & Medicaid Services (CMS) as a High Complexity International Laboratory under the Clinical Laboratory Improvement Amendments (CLIA), specializing in Diagnostic Immunology with a subspecialty in General Immunology (CLIA# 99D2283230). Additionally, we hold a clinical and public health laboratory license with the California Department of Public Health (COS-90013367). Our certification underscores our commitment to rigorous standards.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
Regulated tests: Ensuring Quality and Accuracy
The LDT (Lab Developed Test) designation highlights that our tests are regulated by the Centers for Medicare & Medicaid Services (CMS) under CLIA, ensuring they meet stringent quality and accuracy standards. Unlike commercially distributed tests, which undergo FDA approval, our LDTs are developed and validated within our laboratory to provide specialized and reliable diagnostic insights tailored to your needs. This distinction underscores our commitment to maintaining the highest standards in testing and personalized care.
! The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions. ​